Literature DB >> 2433921

Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures.

R Bugiardini, M Galvani, D Ferrini, C Gridelli, D Tollemeto, N Macri, P Puddu, S Lenzi.   

Abstract

This study reports coronary and systemic hemodynamics, and metabolic responses to atrial pacing, prostacyclin (PGI2), and iloprost, its stable analogue, in 16 patients with severe coronary obstruction as well as predominant narrowing in the left anterior descending artery. PGI2 caused ischemia in six patients with low anginal threshold during pacing. In three of them ischemia was also precipitated by iloprost. Drugs were infused at therapeutic doses and were discontinued when pain occurred. Angina disappeared promptly (less than or equal to 3 minutes) and spontaneously after the infusion of PGI2, whereas after the analogue it was long lasting (greater than or equal to 5 minutes) and was relieved by 125 mg intravenous aminophylline, an antagonist of dipyridamole-induced coronary dilation. Ischemia was associated with a drug-induced decrease in arterial blood pressure and reflex tachycardia, and occurred despite increased great cardiac vein (GCV) blood flow and decreased resistance, which is consistent with either a failure of regional flow to increase proportionally to the metabolic demand or a subendocardial-subepicardial steal. However, the following findings favor the latter hypothesis: heart rate and rate-pressure product at the onset of pain were lower with drugs than with pacing, and GCV blood flow, measured at a comparable heart rate, was less with pacing than with drugs. In conclusion, PGI2 and analogues may induce ischemia in patients with advanced coronary artery disease. The mechanism appears to be related to a dipyridamole-like maldistribution of flow. Counteraction of ischemia can be achieved by aminophylline.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433921     DOI: 10.1016/0002-8703(87)90259-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.

Authors:  L Caspary; A Creutzig; K Alexander
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Coronary artery calibre after direct intra-arterial infusion of epoprostenol (prostacyclin).

Authors:  J Wilson; N P Silverton; M W Baig; E J Perrins; D R Smith; J A Davies; C R Prentice
Journal:  Br Heart J       Date:  1988-11

Review 3.  Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Authors:  K Ver Donck
Journal:  Pharm World Sci       Date:  1994-04-15

Review 4.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

5.  Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.

Authors:  K Sakata; T Hoshino; H Yoshida; T Kaburagi; A Takada
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

Review 6.  Functional and structural adaptations of the coronary macro- and microvasculature to regular aerobic exercise by activation of physiological, cellular, and molecular mechanisms: ESC Working Group on Coronary Pathophysiology and Microcirculation position paper.

Authors:  Akos Koller; M Harold Laughlin; Edina Cenko; Cor de Wit; Kálmán Tóth; Raffaele Bugiardini; Danijela Trifunovits; Marija Vavlukis; Olivia Manfrini; Adam Lelbach; Gabriella Dornyei; Teresa Padro; Lina Badimon; Dimitris Tousoulis; Stephan Gielen; Dirk J Duncker
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 13.081

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.